clinical trial · NCT07160335
A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors
Non-small Cell Lung CancerMelanomaRenal Cell CarcinomaHLX17US-sourced Keytruda®
brief summary
This is a multicenter, randomized, double-blind, parallel-controlled phase I clinical study to evaluate the similarity in PK profile, efficacy, safety, and immunogenicity of HLX17 vs. US-sourced Keytruda® in patients with resected non-small cell lung cancer (NSCLC) or melanoma (MEL), or renal cell carcinoma (RCC).
started
Sep 26, 2025
primary completion
Apr 30, 2027
completion
Mar 27, 2028
last updated
May 15, 2026
official title
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® (US-sourced Keytruda®) in Multiple Resected Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol